Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Sep;270(9):4157-4178.
doi: 10.1007/s00415-023-11787-y. Epub 2023 Jun 8.

Biomarkers in 5q-associated spinal muscular atrophy-a narrative review

H S Lapp  1 , M Freigang  1 , T Hagenacker  2 , M Weiler  3 , C D Wurster  4   5 , René Günther  6   7
Affiliations
Review

Biomarkers in 5q-associated spinal muscular atrophy-a narrative review

H S Lapp et al. J Neurol. 2023 Sep.

Abstract

5q-associated spinal muscular atrophy (SMA) is a rare genetic disease caused by mutations in the SMN1 gene, resulting in a loss of functional SMN protein and consecutive degeneration of motor neurons in the ventral horn. The disease is clinically characterized by proximal paralysis and secondary skeletal muscle atrophy. New disease-modifying drugs driving SMN gene expression have been developed in the past decade and have revolutionized SMA treatment. The rise of treatment options led to a concomitant need of biomarkers for therapeutic guidance and an improved disease monitoring. Intensive efforts have been undertaken to develop suitable markers, and numerous candidate biomarkers for diagnostic, prognostic, and predictive values have been identified. The most promising markers include appliance-based measures such as electrophysiological and imaging-based indices as well as molecular markers including SMN-related proteins and markers of neurodegeneration and skeletal muscle integrity. However, none of the proposed biomarkers have been validated for the clinical routine yet. In this narrative review, we discuss the most promising candidate biomarkers for SMA and expand the discussion by addressing the largely unfolded potential of muscle integrity markers, especially in the context of upcoming muscle-targeting therapies. While the discussed candidate biomarkers hold potential as either diagnostic (e.g., SMN-related biomarkers), prognostic (e.g., markers of neurodegeneration, imaging-based markers), predictive (e.g., electrophysiological markers) or response markers (e.g., muscle integrity markers), no single measure seems to be suitable to cover all biomarker categories. Hence, a combination of different biomarkers and clinical assessments appears to be the most expedient solution at the time.

Keywords: Biomarker; Disease management; Muscle integrity; Spinal muscular atrophy.

PubMed Disclaimer

Conflict of interest statement

None.

Figures

Fig. 1
Fig. 1
Biomarker categories according to the BEST resource (FDA)
Fig. 2
Fig. 2
Possible biomarker sources
See this image and copyright information in PMC

References

    1. So BR, Zhang Z, Dreyfuss G. Chapter 6—the function of survival motor neuron complex and its role in spinal muscular atrophy pathogenesis. In: Sumner CJ, Paushkin S, Ko C-P, editors. Spinal muscular atrophy. Academic Press; 2017. pp. 99–111.
    1. Kolb SJ, Kissel JT. Spinal muscular atrophy. Neurol Clin. 2015;33:831–846. doi: 10.1016/j.ncl.2015.07.004. - DOI - PMC - PubMed
    1. Lorson CL, Hahnen E, Androphy EJ, Wirth B. A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. Proc Natl Acad Sci U S A. 1999;96:6307–6311. doi: 10.1073/pnas.96.11.6307. - DOI - PMC - PubMed
    1. Campbell L, Potter A, Ignatius J, Dubowitz V, Davies K. Genomic variation and gene conversion in spinal muscular atrophy: implications for disease process and clinical phenotype. Am J Hum Genet. 1997;61:40–50. doi: 10.1086/513886. - DOI - PMC - PubMed
    1. Mailman MD, Heinz JW, Papp AC, Snyder PJ, Sedra MS, Wirth B, Burghes AH, Prior TW. Molecular analysis of spinal muscular atrophy and modification of the phenotype by SMN2. Genet Med. 2002;4:20–26. doi: 10.1097/00125817-200201000-00004. - DOI - PubMed